XENIA M 1.25/500MG (Empagliflozin (12.5mg) + Metformin (500mg))

Xenia M 12.5/500 Tablet 10’s is indicated for the management of Type 2 diabetes mellitus, a prevalent condition characterized by elevated blood glucose levels. This chronic illness can significantly impact daily life, necessitating adjustments in dietary habits, medication use, and ongoing medical evaluations to maintain a healthy lifestyle. The formulation combines two antidiabetic agents: Empagliflozin and Metformin. Empagliflozin acts as a sodium-glucose co-transporter-2 (SGLT2) inhibitor, which assists in lowering blood glucose by facilitating the excretion of excess sugar through urine. Metformin, categorized as a biguanide, aids in regulating blood glucose levels, particularly among individuals with obesity, by enhancing insulin sensitivity. The synergy of these two medications results in a more effective reduction of blood sugar levels. It is recommended to administer the tablet orally, with or without food, as prescribed by your healthcare provider, typically once each morning. Dosage adjustments may be required based on individual medical conditions and therapeutic responses. Consistency is crucial for optimal benefits, so taking it at the same time daily can help in this regard. Should there be no improvement or if symptoms worsen, including abnormal blood sugar readings, it is important to consult with your healthcare professional. While some individuals may encounter mild side effects such as increased urination, skin rashes, nausea, vomiting, diarrhea, abdominal pain, or loss of appetite, these typically resolve without the need for medical intervention. It is crucial to inform your doctor if you experience these effects continuously. Before starting this medication, disclose any known allergies to Empagliflozin or Metformin and other sensitivities. The discontinuation of this medication should only occur upon a doctor’s advice, as abrupt cessation may lead to increased blood sugar levels and associated complications, such as vision impairment, kidney damage, or nerve injury. Individuals with type 1 diabetes or severe renal or hepatic conditions should avoid this medication. During pregnancy and lactation, the use of this drug should be evaluated based on its potential risks and benefits in consultation with a healthcare provider.